Press releases
2021
13 December, 2021
Egetis intends to submit a marketing authorisation application for Emcitate® to the European Medicines Agency based on existing clinical data
1 December, 2021
Egetis Therapeutics gets Notice of Allowance for a new US patent for a combination therapy with Aladote
25 November, 2021
CEO and Chairman of the Board in Egetis Therapeutics acquire shares
5 November, 2021
Nomination Committee appointed for the 2022 Annual General Meeting in Egetis Therapeutics
4 November, 2021
Interim report January-September 2021
25 October, 2021
New data confirms long-term efficacy and safety of Emcitate® in MCT8 deficiency patients
8 October, 2021
Egetis Therapeutics receives FDA Fast Track Designation for Emcitate® for MCT8 deficiency
29 September, 2021
Egetis Therapeutics launches disease awareness initiatives to support diagnosis of MCT8 deficiency
9 September, 2021
Egetis receives approval in Turkey for compassionate use of Emcitate® for MCT8 deficiency
26 August, 2021
CEO and senior executives in Egetis Therapeutics acquire shares
19 August, 2021
Emcitate development program progressing according to plan
19 April, 2021
Egetis Therapeutics appoints Yilmaz Mahshid as new CFO
30 March, 2021
Egetis Therapeutics 2020 annual report published
15 February, 2021
Egetis appoints Dr Kristina Sjöblom Nygren as new CMO
10 February, 2021
Aladote presented as a novel emerging treatment of paracetamol overdose at two scientific conferences.
20 January, 2021
Peder Walberg appointed as interim Chief Medical Officer